Risdiplam (Ratni et al. 2018) is the first orally available small molecule approved by the FDA for the treatment of SMA, enhancing the production of functional SMN protein, and represents a significant advancement in the treatment of this genetic disorder. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.